Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KO 2806

Next Previous
X
Search
Drug Profile

KO 2806

Alternative Names: KO-2806

Latest Information Update: 29 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kura Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 27 Feb 2024 Kuro plans a clinical trial for Non-small cell lung cancer (Combination therapy) by mid-2024
  • 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
  • 02 Nov 2023 Kura Oncology plans a phase clinical trial for solid tumors, including clear cell renal cell carcinoma (Late stage disease) and KRASG12C Non small cell lung cancer (Late stage disease) in mid 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top